Efficacy of Solifenacin on Nocturia in Japanese Patients With Overactive Bladder: Impact on Sleep Evaluated by Bladder Diary

Abstract

We compared changes in nocturia and sleep related parameters between the anticholinergic solifenacin and placebo in patients with overactive bladder associated with nocturia. We performed subgroup analysis of data from a randomized, controlled trial of solifenacin (5 or 10 mg) in Japan. Men and women 20 years old or older with overactive bladder were eligible for study participation. Patients who voided at least once during the night at baseline and who completed efficacy and quality of life assessment at baseline and 12 weeks (treatment end) were included in analysis. We compared placebo with the posttreatment change in nocturia and daytime frequency, volume voided per micturition, sleeping time, hours of undisturbed sleep and sleep related quality of life. Subgroup analysis included 962 patients. Solifenacin 10 mg significantly decreased nocturia episodes by 0.46 episodes (p = 0.0449). Solifenacin 5 and 10 mg significantly increased nighttime volume voided per micturition by 30 and 41 ml (p = 0.0033 and <0.0001, respectively). Compared with placebo (33 minutes) the hours of undisturbed sleep significantly increased by 59 and 60 minutes (p = 0.0196 and 0.0195) in patients with solifenacin 5 and 10 mg, respectively. Significant improvement was observed in sleep related quality of life for solifenacin 5 and 10 mg (each p <0.001). Results must be interpreted with caution due to the exploratory nature of this analysis. Solifenacin 10 mg decreases nocturia episodes. Solifenacin 5 and 10 mg increases nighttime volume voided per micturition and may improve quality of sleep and sleep related quality of life in patients with overactive bladder.